Deep brain stimulation
This article was originally published in The Gray Sheet
Deep brain stimulation is "a treatment option" for patients suffering from Parkinson's disease with motor complications, new guidelines from the American Academy of Neurology suggest. The April 3 release of the guidelines was welcome news to Medtronic, which manufactures Activa, one of the deep brain stimulators on the market used to treat that condition. The firm is seeking to broaden the use of Activa to treat obsessive-compulsive disorder and depression (1"The Gray Sheet" April 4, 2005, p. 16)...
You may also be interested in...
Medtronic's pursuit of Activa deep-brain stimulation to treat chronic obsessive-compulsive disorder will serve as a springboard to the lucrative depression market, the company predicts
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.